Panel Discussion: Advancing MRD as a Surrogate Endpoint to Streamline Trial Readouts in Hematology Oncology
Time: 2:00 pm
day: Conference Day 1
Details:
- Optimizing MRD as a surrogate endpoint in oncology trials
- Navigating FDA and regulatory expectations around novel endpoints
- Building successful diagnostic-pharma collaborations to pioneer future trial designs
